Management will lead the discussion, focusing on the company’s diverse portfolio of therapies targeting rare diseases, including treatments for epilepsy, sleep disorders, and oncology. Investors and interested parties are encouraged to register for the call via the company's website. Organizers suggest signing up at least 15 minutes before the broadcast to avoid connection delays.

A replay of the presentation will be archived on the Investor Relations portal of the Jazz Pharmaceuticals website for those unable to attend the live session. The company remains headquartered in Ireland with global research and manufacturing facilities, maintaining its focus on therapeutics for patients with few alternative options.